Directives de traitement du diabète de type 2
(2024) Louvain médical — Vol. 143, n° 04, p. 284-286 (2024)
Files
2024_Hermans_LM_284-286.pdf
Open Access - Adobe PDF
- 77.22 KB
Details
- Authors
- Abstract
- (en) [Treatment guidelines for Type 2 diabetes] The new joint guidelines from the ADA-EASD and the EAS put emphasis on personalizing the choice of the preferential use of molecules from the GLP1-RA and SGLT2-i classes. They have demonstrated cardio-renal benefits beyond their hypoglycemic and weight-lowering effects in Type 2 diabetes (T2DM) patients with proven cardiovascular (CV) damage or high cardio-renal risk. For insulin treated T2DM patients who have benefited from continuous interstitial glucose measurement, reimbursed since 2023, well-defined glucometric targets have been proposed in addition to the usual HbA1c measurement. In addition, the 10-year CV risk can be assessed in T2DM patients undergoing primary cardio-renal prevention, using the recently introduced European SCORE2-Diabetes calculator.
- Affiliations
Citations
Hermans, M. (2024). Directives de traitement du diabète de type 2. Louvain médical, 143(04), 284-286. https://hdl.handle.net/2078.5/216624 (Original work published 2024)